RNA-Nucleic Acid-Activated Protein 181: Potential Drug Target Or Biomarker
RNA-Nucleic Acid-Activated Protein 181: Potential Drug Target Or Biomarker
RNA-Nucleic Acid-Activated Protein 181 (RNF181) is a protein that is expressed in various tissues of the human body, including the liver, pancreas, and gastrointestinal tract. It is a member of the RNA-Nucleic Acid-Activated protein family, which includes several other proteins that have been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
RNF181 is a 21-kDa protein that consists of 115 amino acid residues. It has a characteristic Rossmann-fold structure that is commonly found in proteins that interact with RNA. This structure is responsible for the protein's ability to bind to small RNA molecules, such as microRNAs, which are short snippets of DNA that are produced by the cell's RNA-splicing machinery.
RNF181 has been shown to play a role in various physiological processes in the human body, including cell signaling, metabolism, and inflammation. One of its well-documented functions is its role in the regulation of insulin sensitivity. Insulin sensitivity is a critical factor in the development and progression of type 2 diabetes, and research has suggested that NF181 may be a potential drug target or biomarker for this disease.
RNF181 has been shown to interact with several different small RNA species, including hnRNA, pre-mRNA, and microRNA. It has been shown to bind to stable nuclear small RNA (miRNA) and affect its stability and expression levels. Some studies also suggest that RNF181 plays an important role in regulating insulin sensitivity.
In addition, RNF181 is also closely related to the occurrence and development of various malignant tumors. For example, studies have shown that RNF181 expression levels correlate with the progression and invasiveness of a variety of human tumors. Therefore, the researchers speculated that RNF181 may be a potential tumor target.
In addition, research also shows that RNF181 plays an important role in liver injury and liver disease. The liver is an important metabolic and excretory organ in the human body, and the expression and function of RNF181 in the liver have also been extensively studied. Research shows that RNF181 plays an important role in liver cell damage and repair and may have potential application value in the treatment of liver diseases.
In addition, RNF181 is also closely related to the occurrence and development of various neurological diseases. For example, some studies have shown that RNF181 plays an important role in neurological diseases such as Alzheimer's disease and Parkinson's disease. Therefore, the researchers speculated that RNF181 may be a potential nervous system target.
RNF181 is a protein that plays an important role in various physiological processes. It plays an important role in various physiological processes such as cell signaling, metabolism, and inflammation. At the same time, research also shows that RNF181 plays an important role in a variety of tumors and neurological diseases. Therefore, the researchers speculated that RNF181 may be a potential drug target or biomarker. Future research will further study the function and mechanism of RNF181 in organisms to better understand its role in life processes.
Protein Name: Ring Finger Protein 181
Functions: E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:18331836). Catalyzes monoubiquitination of 26S proteasome subunit PSMC2/RPT1 (PubMed:24811749)
The "RNF181 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF181 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P | RNU105B | RNU11 | RNU12 | RNU2-1 | RNU2-17P | RNU2-2P | RNU2-4P | RNU2-54P | RNU2-5P | RNU2-6P | RNU4-1 | RNU4-14P | RNU4-2 | RNU4-30P | RNU4-33P | RNU4-38P | RNU4-39P
